Durolane, a single-injection hyaluronic acid (HA) product, has been made available by Bioventus for the treatment of pain associated with knee osteoarthritis (OA) in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics (e.g, acetaminophen).
In clinical trials, treatment with Durolane resulted in greater reduction in Visual Analog Scale (VAS) pain scores at 3 and 6 months compared to Synvisc One (hylan G-F 20; Sanofi Genzyme) (P<0.001). In addition, Durolane was associated with longer lasting pain relief (primary outcome: WOMAC pain responder rate) compared with methylprednisolone acetate injection. With regard to safety, the most common adverse events associated with Durolane treatment include arthralgia, injection site pain, and joint swelling.
“Introducing Durolane to the US market gives patients, physicians and payers access to a proven pain reliever for knee OA that has improved the lives of more than 1 million people worldwide,” said Tony Bihl, CEO of Bioventus. “In addition, Durolane is very safe for patients and has more level-1 clinical studies than any other single-injection HA knee therapy on the market today.”
Durolane is available as a 60mg/3mL single-use intra-articular injection.
For more information visit Bioventusglobal.com.